Literature DB >> 10470420

Chemotherapy for brain metastases of lung cancer: a review.

P E Postmus1, E F Smit.   

Abstract

In lung cancer patients brain metastases develop with a high frequency. For years radiotherapy has been the standard treatment for these patients. Here we review the experience with chemotherapy for brain metastases in lung cancer patients. The concept of the brain as pharmacological sanctuary site when brain metastases are present is challenged and it is argued that chemotherapy does play a role in this situation. Recent clinical trials indicate that the combination of chemotherapy and radiotherapy may become the standard treatment for lung cancer patients with brain metastases. It is unclear whether for micrometastatic disease to the brain, blood brain barrier function is of importance for the outcome of chemotherapy in lung cancer patients with respect to the development of overt brain metastases. Areas of improvement of delivery of cytotoxic agents to the brain when brain metastases have not yet developed are discussed.

Entities:  

Mesh:

Year:  1999        PMID: 10470420     DOI: 10.1023/a:1008318515795

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  18 in total

Review 1.  Radiotherapy and chemotherapy of brain metastases.

Authors:  R Soffietti; A Costanza; E Laguzzi; M Nobile; R Rudà
Journal:  J Neurooncol       Date:  2005-10       Impact factor: 4.130

Review 2.  Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future.

Authors:  Claudia Proto; Martina Imbimbo; Rosaria Gallucci; Angela Brissa; Diego Signorelli; Milena Vitali; Marianna Macerelli; Giulia Corrao; Monica Ganzinelli; Francesca Gabriella Greco; Marina Chiara Garassino; Giuseppe Lo Russo
Journal:  Transl Lung Cancer Res       Date:  2016-12

Review 3.  Chemotherapy for metastatic tumors to the central nervous system.

Authors:  C A Conrad
Journal:  Curr Oncol Rep       Date:  2001-11       Impact factor: 5.075

Review 4.  Systemic therapy for brain metastases.

Authors:  Jonathan W Rick; Maryam Shahin; Ankush Chandra; Cecilia Dalle Ore; John K Yue; Alan Nguyen; Garima Yagnik; Soumya Sagar; Saman Arfaie; Manish K Aghi
Journal:  Crit Rev Oncol Hematol       Date:  2019-07-22       Impact factor: 6.312

5.  Use of liposomal doxorubicin-cyclophosphamide combination in breast cancer patients with brain metastases: a monocentric retrospective study.

Authors:  B Linot; M Campone; P Augereau; R Delva; S Abadie-Lacourtoisie; N Nebout-Mesgouez; O Capitain
Journal:  J Neurooncol       Date:  2014-01-31       Impact factor: 4.130

6.  Two cases of leptomeningeal metastases from lung adenocarcinoma which progressed during gefitinib therapy but responded to erlotinib.

Authors:  Satoshi Tetsumoto; Akio Osa; Takashi Kijima; Toshiyuki Minami; Haruhiko Hirata; Ryo Takahashi; Hanako Kuhara; Izumi Nagatomo; Yoshito Takeda; Hiroshi Kida; Sho Goya; Isao Tachibana; Ichiro Kawase
Journal:  Int J Clin Oncol       Date:  2011-05-19       Impact factor: 3.402

Review 7.  Temozolomide for treatment of brain metastases: A review of 21 clinical trials.

Authors:  Wei Zhu; Li Zhou; Jia-Qi Qian; Tian-Zhu Qiu; Yong-Qian Shu; Ping Liu
Journal:  World J Clin Oncol       Date:  2014-02-10

8.  Central nervous system relapse continues to be a therapeutic challenge in extensive disease small-cell lung cancer patients with initial symptomatic brain metastases and good response to chemoradiotherapy.

Authors:  Farkhad Manapov
Journal:  J Neurooncol       Date:  2009-12-15       Impact factor: 4.130

9.  Management of Brain Metastases.

Authors:  Suriya A. Jeyapalan; Tracy Batchelor
Journal:  Curr Treat Options Neurol       Date:  2004-07       Impact factor: 3.598

10.  Clinical analysis of patients who survived for less than 3 months after brain metastatectomy.

Authors:  Young Zoon Kim; Kyu Hong Kim; Joon Soo Kim; Yeong Jin Song; Ki Uk Kim; Hyung Dong Kim
Journal:  J Korean Med Sci       Date:  2009-07-29       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.